Ten U.S. startups completed reverse mergers during Q3 2026, combining with existing public companies or public shells. Biotechnology dominated the group, accounting for six of the 10 transactions, while the remaining startups operated across AI and data infrastructure, robotics and automation, transportation and mobility, and defense technology.
Implied equity values could be established for seven transactions, totaling approximately US$2.03 billion. Alignment Engine had the largest disclosed value at US$500 million, followed by Obsidian Therapeutics at US$413.5 million and Marea Therapeutics at approximately US$351.9 million.
Methodology
This analysis covers U.S. startups that completed qualifying reverse merger transactions between July 1 and September 30, 2026. Completion dates reflect the legal closing of the transaction, rather than its announcement or the first trading day.
A qualifying startup must have been an independently founded, innovation-driven private business built around a scalable product, technology, platform, or business model before the transaction. Traditional businesses without a credible startup identity, subsidiaries of established corporations, internal reorganizations, and businesses that were already publicly traded as the operating startup before the transaction are excluded.
A U.S. startup is a private operating business whose principal headquarters were in the United States immediately before the transaction. For businesses with multiple headquarters or cross-border structures, classification considers where executive management and core operating activities were primarily based. U.S. incorporation, a U.S. stock market listing, or the location of the resulting public parent is not sufficient on its own to establish U.S. startup status.
A transaction qualifies as a reverse merger when a private startup combines with an existing public company or public shell and, based on ownership, control, management, operating business, or the economic substance of the transaction, the private startup becomes the dominant operating or economic side of the resulting public company. The legal description of a transaction as an acquisition, merger, share exchange, or business combination does not by itself determine classification. Conventional acquisitions in which the legacy public company remains the dominant business, IPOs, and SPAC business combinations are excluded.
Implied Equity Value represents the equity value attributed to the private startup under the publicly disclosed merger terms, generally based on the valuation used to determine the merger consideration or exchange ratio. Concurrent financing and any value attributed to the legacy public company are excluded. Where no explicit negotiated startup valuation is disclosed, the issuer-reported fair value of the merger consideration issued for the private startup may be used. Independent estimates derived solely by applying market or financing share prices to merger securities are excluded. A value is reported only when publicly disclosed transaction documents or issuer filings provide sufficient information to establish it; otherwise, it is reported as not disclosed.
Ticker symbols and trading venues describe the resulting public companies following completion. Trading under a new ticker or on a new market may begin after the legal closing date.
Key Findings From U.S. Startup Reverse Mergers in Q3 2026
Biotech Leads Q3 2026 U.S. Startup Reverse Mergers With US$1.49 Billion in Financing
The six biotechnology transactions were associated with approximately US$1.49 billion in private financing. Korsana Biosciences and Obsidian Therapeutics accounted for almost half of that amount, securing US$380 million and US$350 million, respectively. These financings made capital for drug development a central component of the transactions, alongside the startups’ transition into public-company structures.
Three Transactions Accounted for 62% of Disclosed Value
Alignment Engine, Obsidian Therapeutics, and Marea Therapeutics together accounted for approximately US$1.27 billion, or 62% of the US$2.03 billion in identifiable startup equity values. Although biotechnology led by transaction count, AI infrastructure startup Alignment Engine had the largest individual valuation at US$500 million. The other four startups with identifiable values accounted for the remaining 38%.
Public Trading Outcomes Varied Across the Transactions
Seven transactions resulted in Nasdaq-listed companies and one in an NYSE American-listed company. Light Across entered the public markets through OTCID-traded Sharing Economy International, while Blue Laser Fusion became an SEC-reporting public company without an exchange listing or OTC quotation at closing. The transactions therefore provided different levels of access to public trading, with Blue Laser Fusion illustrating how public-company status can precede a stock market debut.
A Closer Look at the 10 U.S. Startup Reverse Mergers Completed in Q3 2026
Alignment Engine
Completion Date: September 11, 2026 | Ticker: SOAR | Exchange: NYSE American | Sector: AI, Data & Infrastructure | Implied Equity Value: US$500 million
Alignment Engine completed its reverse merger with Volato Group, with former Alignment securityholders receiving securities representing 95% of the combined company on an as-converted, fully diluted basis. The preferred shares were non-voting at closing, with conversion subject to further approvals. Alignment Engine develops AI and high-performance computing infrastructure, combining powered data centers, GPU computing, advanced networking, and proprietary technology to support AI training, inference, and other compute-intensive workloads.
Obsidian Therapeutics
Completion Date: August 3, 2026 | Ticker: OBX | Exchange: Nasdaq Capital Market | Sector: Biotech & Pharma | Implied Equity Value: US$413.5 million
Obsidian Therapeutics completed its transaction with Galera Therapeutics, with the resulting public company operating under the Obsidian name and ticker OBX. The clinical-stage biotechnology startup develops engineered tumor-infiltrating lymphocyte cell therapies for solid tumors using proprietary protein-regulation technology designed to improve the control and performance of cell therapies.
Marea Therapeutics
Completion Date: September 17, 2026 | Ticker: LSTA | Exchange: Nasdaq Capital Market | Sector: Biotech & Pharma | Implied Equity Value: US$351.9 million
Marea Therapeutics completed a stock-for-stock reverse merger with Lisata Therapeutics. Marea is developing genetically informed medicines for cardioendocrine diseases, led by MAR001 for severe hypertriglyceridemia and MAR002 for acromegaly. Former Marea equity holders represented the majority of the combined company's fully diluted equity following the transaction.
Korsana Biosciences
Completion Date: September 8, 2026 | Ticker: KRSA | Exchange: Nasdaq Capital Market | Sector: Biotech & Pharma | Implied Equity Value: US$268.4 million
Korsana Biosciences completed its merger with Cyclerion Therapeutics, with the combined company adopting the Korsana name and ticker KRSA. Korsana develops therapies for neurodegenerative diseases using its THETA platform, which is designed to transport therapeutic molecules across the blood-brain barrier. Its lead program, KRSA-028, targets amyloid beta for Alzheimer's disease.
Vidya Therapeutics
Completion Date: July 28, 2026 | Ticker: PCSA | Exchange: Nasdaq Capital Market | Sector: Biotech & Pharma | Implied Equity Value: US$175 million
Vidya Therapeutics completed an all-stock merger with Processa Pharmaceuticals, bringing its lead candidate VT-7208 into the resulting company's pipeline. Vidya is a clinical-stage biotechnology startup developing VT-7208, a CNS-penetrant Bruton's tyrosine kinase inhibitor targeting immune-mediated diseases including food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.
Yarrow Bioscience
Completion Date: July 27, 2026 | Ticker: YARW | Exchange: Nasdaq Capital Market | Sector: Biotech & Pharma | Implied Equity Value: US$172.9 million
Yarrow Bioscience completed its merger with VYNE Therapeutics, after which Yarrow's business became the primary business of the combined company and the company adopted the Yarrow name. Yarrow is developing therapies for autoimmune thyroid diseases, led by YB-101, an anti-TSHR antibody being developed for Graves' disease and thyroid eye disease.
Kira Pharmaceuticals
Completion Date: July 16, 2026 | Ticker: JSPR | Exchange: Nasdaq Capital Market | Sector: Biotech & Pharma | Implied Equity Value: US$150 million
Kira Pharmaceuticals completed an all-stock merger with Jasper Therapeutics. Kira develops complement-targeted therapies for immune-mediated diseases, including programs targeting multiple pathways within the complement cascade. Immediately after the merger and before the concurrent financing, former Kira shareholders represented the large majority of the combined company's fully diluted equity.
Light Across
Completion Date: August 2, 2026 | Ticker: SEII | Market: OTC Markets - OTCID | Sector: Transportation & Mobility | Implied Equity Value: Not disclosed
Light Across completed a reverse acquisition with Sharing Economy International through a share exchange. Light Across shareholders received 80% of the resulting company's outstanding common stock, and Light Across became its principal operating business. The startup focuses on electric vehicle engineering, design, and manufacturing alongside mobility-related technologies and services.
MBody AI
Completion Date: August 26, 2026 | Ticker: MBAI | Exchange: Nasdaq Capital Market | Sector: Robotics & Automation | Implied Equity Value: Not disclosed
MBody AI completed its merger with Check-Cap, bringing its embodied artificial intelligence business into the Nasdaq-listed company. MBody AI develops a hardware-agnostic software platform for autonomous systems and deploys service robots in commercial environments, including hospitality, gaming, and large-property operations.
Blue Laser Fusion
Completion Date: September 4, 2026 | Ticker: N/A | Market: Not listed or quoted at closing | Sector: Defense, Security & Public Safety | Implied Equity Value: Not disclosed
Blue Laser Fusion completed a reverse triangular merger with Unite Acquisition 2 Corp., which was a public shell before the transaction. Blue Laser Fusion is developing its GigaPulse pulsed-laser architecture for directed-energy defense and inertial fusion energy applications. The resulting company continued as an SEC-reporting public company but was not listed on an exchange or quoted on an OTC market at closing.
Q3’s transactions show that the significance of a reverse merger extends beyond public-company status. For biotechnology startups, substantial financing was a central part of the deals. Elsewhere, the transactions redirected public vehicles toward new operating businesses. The practical outcomes depended on the capital secured, the ownership rights granted, and whether the resulting company’s shares were available for public trading.